Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives

Table 3 Efficacy of sorafenib and transarterial chemoembolization in hepatocellular carcinoma (sequential therapy not included) according to current phase I-II studies

Author	Year	Phase	Investigational drug	n	RR	DS	PFS/TTP	OS
Chow et al[45]	2010	II	Sorafenib + SIRT	35	31.4	77.1	NR/NR	10.8
Chung et al[47]1	2010	II	Sorafenib + TACE	50	NR2	96	NR/NR	NR
Dufour et al[48]	2010	I	Sorafenib + TACE	14	NR3	NR3	NR3	NR3
Erhardt et al[46]1	2009	II	Sorafenib + TACE	44	NR4	63.6	8.0/16.1	11.7
Reyes et al[49]1	2009	II	Sorafenib + DEB-TACE	50	NR5	NR	NR/NR	NR

¹Interim analysis;

²20/50 patients received 2 cycles of transarterial chemoembolization (TACE), only, and 18 of these 20 patients achieved complete response compared to 2 patients with progressive disease. 30/50 patients received more than 2 cycles of TACE and achieved partial response or stable disease;

³Primary objective of this prospective trial was evaluation of safety and tolerability of a continuous regimen of sorafenib combined with TACE;

⁴According to 31 patients who received at least 1 cycle of TACE, 2/31 (6.5%) showed complete response, 15/31 (48.4%) showed partial response, and 11/31 (35.5%) showed stable disease. PFS, TTP, and OS are given for all 44 patients enrolled at time point of interim analysis;

⁵Patients who completed DEB-TACE showed 100% objective tumor response and 100% partial response or stable disease according to EASL or RECIST criteria, respectively. DEB-TACE: (Drug eluting beads)-transarterial chemoembolization; NR: Not reported; DS: Disease stabilization (%); OS: Overall survival (mo); PFS/TTP: Progression free survival/time to progression (mo); PFS-6m: Progression free survival rate at 6 mo (%); RR: Response rate [complete + partial response (%)]; SIRT: Selective internal radio therapy.